© 2004 European Society of Cardiology
C-reactive protein co-expresses with tumor necrosis factor-
in the myocardium in human dilated cardiomyopathy
Second Department of Internal Medicine Iwate Medical University School of Medicine, Uchimaru 19-1, Morioka 020-8505, Iwate, Japan E-mail address: m_satoh{at}imu.ncvc.go.jp
* Corresponding author. Tel.: +81 19 651 5111; fax: +81 19 651 0401.
 |
Abstract |
|---|
Background: C-reactive protein (CRP) has recently been reported to be present in cardiac tissue and to stimulate the production of proinflammatory cytokines. Cardiac expression of tumor necrosis factor-
(TNF-) plays an important role in the pathogenesis of dilated cardiomyopathy (DCM).
Aims: To determine whether CRP co-expresses with TNF- in the myocardium and to examine its association with clinical features in patients with DCM.
Methods and results: Endomyocardial biopsy tissues were obtained from 41 DCM patients and 16 controls by right ventricular endomyocardial biopsy. Levels of CRP and TNF- mRNA were measured by real-time RT-PCR. Immunohistochemistry and in situ hybridization were performed to identify the cellular sources of CRP and TNF-. Both CRP and TNF- mRNA were expressed in myocardium obtained from DCM patients, but not in controls. A positive correlation was found between CRP and TNF- levels. CRP/TNF- double staining was found to be colocalized in the cardiomyocytes of DCM patients. Both forms of mRNA were also expressed in cardiomyocytes. Both CRP and TNF- mRNA levels were negatively correlated with systolic function and positively correlated with left ventricular volume in DCM patients. These mRNA levels were lower in DCM patients treated with a combination of spironolactone and either angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II type 1 receptor blockers (ARBs) than in patients not treated with these drugs.
Conclusion: Cardiac expression of CRP with TNF- may function as a proinflammatory mediator in DCM and may be related to the clinical severity of DCM. Expression of both of these proteins was decreased in DCM patients receiving spironolactone and either ACEIs or ARBs.
Key Words: Immunohistochemistry • Inflammation • In situ hybridization • Myocardium • Polymerase chain reaction • Remodeling
Received May 18, 2004; Revised August 23, 2004; Accepted October 20, 2004
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Mantovani, C. Madeddu, C. Cadeddu, M. Dessi, A. Piras, E. Massa, R. Serpe, G. Antoni, and G. Mercuro Persistence, Up to 18 Months of Follow-Up, of Epirubicin-Induced Myocardial Dysfunction Detected Early by Serial Tissue Doppler Echocardiography: Correlation with Inflammatory and Oxidative Stress Markers Oncologist, December 1, 2008; 13(12): 1296 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mercuro, C. Cadeddu, A. Piras, M. Dessi, C. Madeddu, M. Deidda, R. Serpe, E. Massa, and G. Mantovani Early Epirubicin-Induced Myocardial Dysfunction Revealed by Serial Tissue Doppler Echocardiography: Correlation with Inflammatory and Oxidative Stress Markers Oncologist, September 1, 2007; 12(9): 1124 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Zimmermann, M. Kochs, T. P. Zwaka, M. Bienek-Ziolkowski, M. Hoher, V. Hombach, and J. Torzewski Prognostic role of myocardial tumor necrosis factor-alpha and terminal complement complex expression in patients with dilated cardiomyopathy Eur J Heart Fail, January 1, 2007; 9(1): 51 - 54. [Abstract] [Full Text] [PDF]
|
|